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SUMMARY
Objective: Evaluate the seizure-reduction response and safety of mesial temporal lobe
(MTL) brain-responsive stimulation in adults with medically intractable partial-onset
seizures ofmesial temporal lobe origin.
Methods: Subjects with mesial temporal lobe epilepsy (MTLE) were identified from
prospective clinical trials of a brain-responsive neurostimulator (RNS System, Neuro-
Pace). The seizure reduction over years 2–6 postimplantationwas calculated by assess-
ing the seizure frequency compared to a preimplantation baseline. Safety was assessed
based on reported adverse events.
Results: There were 111 subjects with MTLE; 72% of subjects had bilateral MTL onsets
and 28% had unilateral onsets. Subjects had one to four leads placed; only two leads
could be connected to the device. Seventy-six subjects had depth leads only, 29 had
both depth and strip leads, and 6 had only strip leads. The mean follow-up was 6.1 
(standard deviation) 2.2 years. The median percent seizure reduction was 70% (last
observation carried forward). Twenty-nine percent of subjects experienced at least
one seizure-free period of 6 months or longer, and 15% experienced at least one sei-
zure-free period of 1 year or longer. There was no difference in seizure reduction in
subjects with and withoutmesial temporal sclerosis (MTS), bilateral MTL onsets, prior
resection, prior intracranial monitoring, and prior vagus nerve stimulation. In addi-
tion, seizure reduction was not dependent on the location of depth leads relative to
the hippocampus. Themost frequent serious device-related adverse event was soft tis-
sue implant-site infection (overall rate, including events categorized as device-related,
uncertain, or not device-related: 0.03 per implant year, which is not greater than with
other neurostimulation devices).
Significance: Brain-responsive stimulation represents a safe and effective treatment
option for patients with medically intractable epilepsy, including patients with unilat-
eral or bilateral MTLE who are not candidates for temporal lobectomy or who have
failed a prior MTL resection.
KEY WORDS: Closed-loop, Neuromodulation, Partial seizures, Hippocampus, Focal
stimulation.
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Temporal lobectomy is the most effective treatment for
many patients with medically intractable mesial temporal
lobe epilepsy (MTLE). However, 25–35% of patients with
MTLE who are treated with resective or ablative surgeries
do not achieve sustained seizure freedom, and others are not
candidates for surgery because the risks, particularly to
memory or language, are too high.1–5 Neuromodulation
therapies are a treatment option for some of these patients.
Brain-responsive (closed-loop) neurostimulation (RNS
System) is a safe and effective adjunctive treatment to
reduce the frequency of seizures in medically refractory
adults with partial-onset seizures.6–8 However, the results
specific to subjects with MTLE have not been published
previously.
This report provides an analysis of the long-term results
of responsive MTL stimulation in subjects with MTLE par-
ticipating in the RNS System clinical trials. This experience
may assist physicians when counseling patients who are
considering or being treated with brain-responsive
stimulation.
Methods
The RNS System (NeuroPace, Mountain View, CA,
U.S.A.) provides brain-responsive stimulation directly to
one or two seizure foci when abnormal electrocortico-
graphic (ECoG) activity is detected. A cranially implanted
programmable neurostimulator is connected to one or two
depth or cortical strip leads that are surgically placed at one
or two previously identified seizure foci. Each lead contains
four electrode contacts. The neurostimulator continually
senses ECoG activity and is programmed by the physician
to detect specific ECoG patterns, typically abnormal activ-
ity that has been observed at the onset of electrographic sei-
zures. Once detection settings are refined for a patient, the
neurostimulator is programmed to deliver brief stimulus
pulses through the electrodes in response to detections. In
addition, the neurostimulator stores ECoG samples. The
physician continues to adjust detection and stimulation
parameters as needed for each patient.
The study protocols have been described elsewhere.6–8
A largely open-label Feasibility study assessed safety and
followed adults with medically refractory partial-onset
epilepsy over a 3-month preimplantation baseline and a
2-year postimplantation treatment period. A randomized
controlled trial (Pivotal study) enrolled adults with medi-
cally intractable partial epilepsy and an average of three
or more partial seizures per month. A 3-month baseline
was followed by a 1-month postimplantation stabilization
period and then by a 4-month blinded period during which
subjects were randomized 1:1 to receive active or sham
stimulation. All subjects received active stimulation in a
subsequent open-label period to collect safety and efficacy
data to 2 years postimplantation. Once subjects completed
either the Feasibility or Pivotal study, they could continue
in a 7-year follow-on Long-term Treatment (LTT) study.
The study was ongoing as of the data cutoff on November
1, 2014.
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Key Points
• Responsive stimulation is a well-tolerated treatment
option for patients with MTLE who are not candidates
for a temporal lobe resection
• Median seizure reductions were 70% using a last
observation carried forward analysis
• Twenty-nine percent of patients reported periods of
seizure freedom lasting ≥6 months and 15% reported
seizure-free periods ≥1 year
• Seizure reductions were not dependent on any clinical
characteristics including MTS, bilateral onsets, prior
resection, and prior VNS
• Seizure reductions were similar in patients with depth
leads placed within or adjacent to the hippocampus
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Subjects
Subjects with MTLE who participated in clinical trials of
the RNS System were included in the analyses. Study proto-
cols were approved by the institutional review boards of
participating investigation sites. All subjects provided writ-
ten informed consent. The studies were registered on
www.clinicaltrials.gov (NCT00079781, NCT00264810,
and NCT00572195).
Long-term seizure reduction
Long-term results over years 2–6 postimplantation were
measured as median percent change in seizures and respon-
der rate (the percentage of subjects with a 50% or greater
reduction in seizures) for each 3-month period compared to
the preimplantation baseline. Seizure data were collected
using seizure diaries.
In addition, last observation carried forward (LOCF)
analyses based on the most recent 3 months of available
open-label seizure diary data for each subject were per-
formed. This ensured that the results were not influenced by
subjects who discontinued or those who had not yet com-
pleted 6 years of follow-up.
Long-term seizure reduction by demographic
characteristics
Seizure reduction was compared for subjects with bilat-
eral and unilateral MTL seizure onsets, and according to
prespecified characteristics that could potentially affect the
clinical response to treatment. These included whether the
subject had mesial temporal sclerosis (MTS), had intracra-
nial monitoring for localization, or had been treated with
vagus nerve stimulation (VNS) or temporal lobectomy. A
logistic generalized estimating equation (GEE) model was
fit to the results for mean percent change for each 3-month
period from the beginning of year 2 through the end of year
6 for each of the comparisons. GEE is an extension of gener-
alized linear modeling that handles missing data and
properly assigns significance to multiple correlated mea-
surements. The percent change in seizure rate for all avail-
able 3-month epochs was analyzed using a GEE model with
a compound symmetric correlation structure.9 p-Values
were based on empirical standard errors. For all compar-
isons, a was set to p < 0.05. In addition, median percent
change and responder rate using LOCF were calculated for
each clinical characteristic.
Depth lead placement
Depth lead location relative to the hippocampus was
determined for subjects with preimplantation magnetic res-
onance imaging (MRI) and postimplantation computed
tomography (CT) coregistered images. The coregistered
images were reviewed by two independent neurosurgeons
who categorized a depth lead as within the hippocampus if
at least two of the four electrode contacts were in the hip-
pocampus, and outside of the hippocampus if more than two
of the four contacts were not in the hippocampus. Seizure
reduction was assessed using the GEE and LOCF analysis
methods described earlier.
Long-term Safety
Safety was assessed as the rate and types of sponta-
neously reported serious and mild adverse events (AEs)8
and classified by the investigator as device related (defi-
nitely or potentially related to the RNS System) or not. An
independent Data Monitoring Committee reviewed all AEs
and a second committee determined whether deaths met cri-
teria for sudden unexpected death in epilepsy (SUDEP).
Results
There were 111 subjects with MTLE treated with respon-
sive stimulation during the Feasibility (N = 16) and Pivotal
(N = 95) studies, and 102 subjects continued into the LTT
study. Subject accountability and reasons for discontinua-
tion are provided in Figure 1. The mean follow-up at the
time of data cutoff was 6.1  (standard deviation)
2.2 years, and the accumulated experience was 671 patient
implant years and 631 patient years during which responsive
MTL stimulation was provided.
Demographic characteristics
Demographic characteristics are provided in Table 1.
Most subjects had frequent seizures for many years and had
failed treatment with multiple antiepileptic medications and
in some cases VNS (24%) or temporal lobectomy (12%).
MTS was present in 55% of subjects. Ictal onsets were bilat-
eral in 72% of subjects and unilateral in 28% (68% left;
32% right). Sixty percent of subjects with unilateral right
onsets had undergone a temporal lobectomy (three right;
three left).
Lead placement approaches
Subjects had one to four leads placed during the initial
procedure: one lead (n = 1); two leads (n = 92); three leads
(n = 4); and four leads (n = 14). Only two depth leads
could be implanted and only two leads of any type could be
connected to the device at a time. Seventy-six subjects had
only depth leads placed, 29 had both depth and strip leads,
and 6 had only strip leads. Most depth leads were implanted
along the longitudinal axis of the hippocampus. Cortical
strip leads were typically placed subtemporally. CT scans
showing common lead implantation strategies are provided
in Figure 2(A–C).
Of the 13 subjects with a prior temporal lobectomy, leads
were contralateral (n = 6), ipsilateral (n = 2), or both
(n = 5) to the resection. All subjects had at least one depth
lead.
Epilepsia, 58(6):994–1004, 2017
doi: 10.1111/epi.13740
996
E. B. Geller et al.
Sixty-two of the subjects had coregistered MRI and CT
images with sufficient resolution for localizing the depth
leads. In 31 subjects, at least one depth lead was positioned
in the hippocampus. The remaining 31 subjects had depth
leads near but not within the hippocampus. Figure 2(D–E)
shows bilateral depth lead placements in two subjects; one
with leads within the hippocampus and one with leads ven-
tral to the hippocampus.
Figure 3 shows representative ECoG recordings from
MTLE subjects. Stimulation was commonly delivered to
hypersynchronous and low-voltage fast electrographic
activity. Typical stimulation settings were: 1.5–2.5 lC/cm2
(range 0.1–19.0 lC/cm2); 1.0–3.0 mA (range 0.5–
12.0 mA); 200 Hz (range 1–333 Hz); 160 lsec pulse width
(range 80–1000 lsec); and 100 msec burst duration (range
10–5,000 msec). The median number of programming
changes from the beginning of the second-year postimplan-
tation to the end of the data analysis period was 3 per year
per subject (range 1–7). These programming changes
included adjustments to stimulation, detection, or both.
Long-term seizure reduction
The long-term response to treatment with MTL respon-
sive stimulation is presented in Figure 4. Disabling seizures
were reduced by a median 66.5% (interquartile range [IQR]
31.8–93.7%) at 6 years, and the 50% responder rate reached
64.6% (95% confidence interval [CI] 53.8–74.1%). Using
LOCF, disabling seizures were reduced by a median of 70%
(IQR 31.8–92.9%; n = 106), and the responder rate was
66% (95% CI 56.6–74.4%). No seizures were reported by
20.8% of subjects in the last 3 months. Over the entire
open-label period, 45% (50/111) of subjects reported sei-
zure-free intervals lasting ≥3 months, 29% ≥6 months (32/
111), and 15% ≥1 year (17/111).
There were no statistically significant differences, by
GEE, in seizure reduction between subjects with and with-
out MTS (p = 0.42), between subjects with bilateral and
Figure 1.
Subject Progression.1Two subjects
discontinued prior to completing
the study. 2Nine subjects
discontinued prior to completing
the study; two of those subjects
subsequently enrolled in the Long-
term Treatment study. 3Reasons for
withdrawal: to pursue other
treatments (2); subject chose not to
replace neurostimulator after
expected battery depletion (4);
insufficient efficacy (2); subject
chose not to replace
neurostimulator after resolution of
infection (2); transfer of medical
care at nonstudy center (1); non-
compliance (3); ongoing suicidality/
noncompliance (1). 4Study ongoing;
data as of November 1, 2014.
Epilepsia ILAE
Table 1. Subject demographics and characteristics.
Characteristic Mean  SD (range) or % (n/N)
Female 48% (53/111)
Age in yearsa 37.3  11.3 (18–60)
Duration of epilepsy in yearsa 19.8  12.7 (2–57)
Number of AEDsa 2.7  1.1 (1–6)
Baseline monthly seizure frequency 15.1  25.0 (1–217)b
median = 7.7
Prior intracranial monitoring 46% (51/111)
Prior epilepsy surgery 12% (13/111)
Prior treatment with VNS 24% (27/111)
Bilateral MTL seizure onsets 72% (80/111)
Unilateral MTL seizure onsets 28% (31/111)
Left unilateral MTL 68% (21/31)
Right unilateral MTL 32% (10/31)
Mesial temporal sclerosis 55% (61/111)
aAt enrollment in originating study.
bThe lower end of the monthly seizure range was for a single subject in the
RNS Feasibility Study who enrolled based on simple partial sensory seizures
and did not have other disabling seizures during the baseline period.
AEDs, antiepileptic medications; VNS, vagus nerve stimulation.
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unilateral onsets (p = 0.97), between subjects localized
with intracranial monitoring and those not (p = 0.15), and
between those treated and not treated previously with VNS
(p = 0.78) or epilepsy surgery (p = 0.54). Table 2 provides
the median percent change and responder rates using an
LOCF analysis for each of the demographic characteristics.
In addition, there were no statistically significant differ-
ences in seizure reduction between subjects with at least one
depth lead in the hippocampus and subjects with depth leads
outside of the hippocampus (GEE, p = 0.9). The LOCF
median percent reduction in seizure rate was 77.8% (IQR
32.3–100%; n = 31) for the hippocampal group and 60.2%
(IQR 29.9–87.8%; n = 31) for the MTL extrahippocampal
group. The LOCF responder rates were 67.7% (95% CI
50.1–81.4%) and 61.3% (95% CI 43.8–76.3%),
respectively.
Device-related serious adverse events
There were only two device-related (related or uncertain
as categorized by the investigator) serious adverse events
(SAEs) that occurred in ≥5% of the 111 subjects over the
671 patient implant years. The SAEs were implant-site
infection and device lead damage, described in detail in
subsequent text.
A
D1 D2
E1 E2
B C
Figure 2.
Common RNS Lead placement strategies for mesial temporal lobe epilepsy. (A) Bilateral depth leads targeting the hippocampus. (B) A
depth lead targeting the hippocampus and a cortical strip lead targeting the anterior subtemporal region in a subject with unilateral mesial
temporal seizure onsets. (C) Bilateral depth and cortical strip leads. The depth leads target the hippocampal region bilaterally and are con-
nected to the neurostimulator. The cortical strip leads targeted the subtemporal regions bilaterally but are not connected to the neu-
rostimulator. (D1 & D2) Co-registered postoperative CT and preoperative MRI scan for an individual subject with bilateral depth leads
that met the criteria for being classified as “in” the hippocampus. Cross-hairs identify an electrode within the left (D1) and right (D2) hip-
pocampi. (E1 & E2) Co-registered postoperative CT and preoperative MRI scan for an individual subject with bilateral depth leads that
met the criteria for being “out” and ventral to the hippocampus. Cross-hairs identify an electrode outside the left (E1) and right (E2)
hippocampi.
Epilepsia ILAE
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Implant-site infection
There were 15 SAEs (device-related or uncertain)
occurring in 13 subjects (11.7%). All infections were
superficial soft tissue only and there were no long-lasting
neurologic or medical consequences. The implant-site
infections occurred during the immediate postoperative
period for three of the subjects; one had the neurostimula-
tor and leads explanted. For the remaining subjects, the
implant-site infection occurred beyond the immediate
postoperative period; seven occurred within 3 months of a
neurostimulator replacement. All subjects were treated
with antibiotics; nine had their neurostimulator explanted,
and six were later reimplanted.
In addition, two subjects experienced implant-site infec-
tions that were categorized as not device related. The infec-
tions occurred during the immediate postoperative period.
Both were treated with antibiotics; one subject had the neu-
rostimulator explanted and subsequently reimplanted.
Another two subjects experienced implant-site infections
as a result of seizure-related injuries. Both subjects had their
devices and leads explanted.
Finally, three SAEs related to implant-site skin erosion
were reported in two subjects. Two events were reported in
one subject; the events occurred over 7.5 years apart. The
first event resolved with antibiotics and surgical removal of
the device, and the subject was reimplanted. However, the
neurostimulator was explanted and not replaced following
the second event. For the second subject, the SAE resolved
with antibiotics and device removal. They were reimplanted
with no further complications.
The overall rate of SAEs due to infection was 0.03 per
patient implant year.
Device lead damage
Seven subjects (6.3%) required lead replacement due to
lead damage. The overall rate of SAEs due to lead damage
was 0.01 per patient implant year.
Other adverse events of interest
Intracranial hemorrhage
Three subjects (2.7%) had a serious AE related to
intracranial hemorrhage (two were categorized as device-
related). One was a CT-diagnosed asymptomatic intraven-
tricular hemorrhage within the first days after bilateral
depth-lead implant. The second subject sustained a sub-
arachnoid hemorrhage following seizure-related head
trauma. Neither of these events had any neurologic
Figure 3.
Representative time series and
corresponding spectrograms
demonstrating the
electrocorticographic activity
recorded by the RNS System in
patients with bilateral and unilateral
MTLE. (A1) Hypersynchronous high
amplitude spike onset on channels 3
and 4 (right hippocampal depth) in a
subject with bilateral MTLE and depth
leads targeting the hippocampus
bilaterally. (A2) Low voltage fast
onset on channels 1 (left depth), 3
and 4 (right depth) in a second
subject with bilateral MTLE and
bilateral depth leads targeting the
hippocampus. (B1) Electrographic
seizure onset on channels 1 and 2
(left hippocampal depth) for a subject
with unilateral MTLE. The event
subsequently spreads to the lateral
temporal subdural strip lead
(channels 3 and 4). (B2)
Electrographic seizure onset on both
the strip (channels 1 and 2) and depth
(channels 3 and 4) leads.
Epilepsia ILAE
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sequelae. The final subject had a subtemporal hematoma
2.5 years after implantation of two depth leads and two cor-
tical strip leads. The subject experienced headaches that
subsequently resolved.
In addition, one subject reported a mild AE related to a
small postoperative subdural hematoma near the site of
the neurostimulator and leads that resolved without
intervention.
Death
There were 6 deaths in the 111 subjects over the 671
patient implant years and 631 patient stimulation years. One
subject had a history of depression and died by suicide. Five
deaths were attributed to possible (n = 2), probable (n = 1),
or definite (n = 2) SUDEP; two of these occurred while
brain-responsive stimulation was off. Stimulation had been
disabled in the first subject for >200 days, and the second
subject had not yet had stimulation enabled after the initial
implant. None of the SUDEP events were deemed to be
related to the device.
Photopsia
Transient mild AEs related to photopsia that were
deemed to be related to the device or of uncertain device
relation were reported in 16 subjects (14.4%). All but one
event resolved spontaneously or with changes to the stimu-
lation parameters.
Memory impairment
Transient mild AEs related to memory impairment that
were deemed to be related to the device or of uncertain
device relation were reported in seven subjects (6.3%). All
of these subjects had memory impairment on preimplant
baseline neuropsychological assessment.
Depression
Two subjects (1.8%) reported transient SAEs related to
depression with suicidal ideation that were deemed to be
related to the device or of uncertain device relation. Both
subjects had a prior history of depression and one had a
prior history of a suicide attempt. In addition, as men-
tioned earlier, one MTL subject committed suicide during
the trial. This subject also had a prior history of depres-
sion and suicidal ideation.
Mild AEs related to depression deemed to be of uncertain
device relation were also reported in four subjects (3.6%).
Two of the four subjects met criteria for moderate depres-
sion at baseline by validated mood inventory (Beck Depres-
sion Inventory-II; BDI-II) and/or reported a prior medical
history of depression.
Figure 4.
Long-term response to brain responsive stimulation in patients with MTLE. (A) Median percent change in total disabling seizures in each
3-month bin beginning in Year 2 postimplantation. Error bars indicate interquartile ranges (25th–75th). (B) Responder Rate (percent of
patients with a ≥50% reduction in total disabling seizures) in each 3-month bin beginning in Year 2 post-implantation. Error bars indicate
95% confidence intervals.© 2017 NeuroPace, Inc.
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Discussion
Brain responsive MTL stimulation is a new treatment for
patients with medically intractable MTLE who are not good
resection candidates. Hippocampal stimulation in patients
with MTLE has shown efficacy and good tolerability in
several small series.10–20 This is the first report of a large
cohort of subjects treated with responsive mesial temporal
stimulation.
In selected patients with medically intractable MTLE,
anterior temporal lobectomy or amygdalohippocampec-
tomy are often the procedures of choice, with long-term sei-
zure-freedom rates of 60–75%.21 Ablative procedures may
also be an option for some.22 However, many patients are
not candidates for resective or ablative procedures. Seizures
may arise from both temporal lobes or the risk to memory,
language, or other neurologic functions is not acceptable.
Many of the 111 subjects with medically refractory MTLE
enrolled in the RNS System trials had bilateral MTL seizure
onsets. Most of the subjects with unilateral onsets had sei-
zures arising from the dominant temporal lobe and/or had
already undergone a temporal lobectomy. Thus, the subjects
included in the RNS System trials were not considered to be
good surgical candidates.
Seizure reduction was substantial and sustained. Nearly
half of the subjects experienced at least one ≥3-month per-
iod without seizures, and 15% were without seizures for
1 year or longer. Treatment with responsive stimulation
achieved reductions in seizure frequency reaching 70% over
6 years of prospective follow-up. This contrasts favorably
with continued medical management in refractory nonsurgi-
cal candidate patients with MTLE, where sustained reduc-
tions in seizures are not typically observed.5,23
Seizure reductions for MTLE subjects who had intracra-
nial monitoring were similar to those for subjects who did
not. The criteria by which an individual epilepsy center
chose to localize the seizure focus or foci were not standard-
ized within the clinical trials. Therefore, no comment about
the optimal localization testing to identify patients who
would benefit from responsive stimulation can be provided
from this experience. However, intracranial monitoring was
not required for subjects to achieve a good response. In fact,
because it may take several weeks of chronic ambulatory
monitoring to establish that a patient with MTLE has inde-
pendent bilateral mesial temporal seizures,24 there is a
chance that lateralization of MTLE may not be adequate
within a 1- to 2-week hospitalization for EEG monitoring,
even with intracranial electrodes.
There was no difference in seizure reduction between
subjects with and without MTS. The lack of a significant
difference in seizure reduction contrasts with earlier reports
by Velasco et al.,18 in a small sample (n = 5 with MTS;
n = 4 without) in which there was a greater and earlier
reduction in seizures for MTLE patients with negative MRI
findings. Future trials with standardized and sophisticated
neuroimaging are required to better understand how neu-
roimaging might be used to optimize selection of patients
for MTL responsive stimulation. In the short-term, however,
patients with and without MTS can be considered candi-
dates for responsive stimulation.
The experience with responsive MTL stimulation thus far
suggests that leads need not be placed precisely within the
hippocampus, since stimulation was as effective when MTL
leads were placed within the hippocampus or nearby.
Whether a larger volume of tissue activation was required
for comparable seizure control when leads were outside the
hippocampus was not assessed. However, these results are
consistent with a smaller series in eight MTLE patients
receiving hippocampal stimulation.11 Decreases in epilepto-
genic activity were related to proximity of the active elec-
trode(s) to the subiculum and not associated with the
proximity of the active electrode(s) to the ictal focus. Future
research will explore whether stimulation should be deliv-
ered directly to the seizure focus, near the focus, or in rele-
vant propagation pathways or networks and will evaluate
what volume of tissue activation may be required for each
stimulation target. In addition, future research will also
evaluate whether other techniques such as tractography or
Table 2. LOCF by clinical demographic characteristic
Covariate N Median % changea (IQR) Responder ratea (95% CI)
Prior intracranial monitoring Yes 48 74.5% (29.2% to95.4%) 66.7% (52.5% to 78.3%)
No 58 67.6% (33.8% to91%) 65.5% (52.7% to 76.4%)
Mesial temporal sclerosis Yes 58 60.6% (30.5% to89.2%) 60.3% (47.5% to 71.9%)
No 48 75.6% (39.5% to95.5%) 72.9% (59% to 83.4%)
Bilateral MTL onsets Yes 75 67.9% (30% to90%) 64.5% (53.3% to 74.3%)
No 30 72.5% (37% to95.9%) 70% (52.1% to 83.3%)
Prior epilepsy surgery Yes 12b 72.5% (57.4% to93.5%) 91.7% (64.6% to 98.5%)
No 95 69.6% (29.8% to92.9%) 62.8% (52.7% to 71.9%)
Prior VNS Yes 27 56.8% (27.5% to81%) 63% (44.2% to 78.5%)
No 78 74.1% (32.8% to100%) 67.1% (56.1% to 76.4%)
IQR, Interquartile range, 25th to 75th percentile; VNS, vagus nerve stimulation.
aObserved change in the most recent 3 months (LOCF).
bSmall n.
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intraoperative electrocorticography could provide insight
into the ideal lead placement for an individual patient.
Responsive MTL stimulation was equally effective in
subjects with bilateral or unilateral seizure onsets. There has
been another report of successful treatment of bilateral as
well as unilateral MTL seizures with direct brain stimula-
tion.25 This series also suggested that some patients with
unilateral onsets who do not respond to unilateral MTL
stimulation may improve when stimulation is provided
bilaterally.
About one fourth of the MTLE subjects participating in
the RNS System trials were previously treated with VNS.
These subjects were as likely to benefit from responsive
stimulation as the subjects who had not been treated with
VNS. The mechanisms by which VNS and direct brain stim-
ulation act to improve seizure control, while not completely
understood, are likely quite different, suggesting that a fail-
ure to respond to one does not predict response to the other.
Some patients who have not achieved seizure control
after temporal lobe resection may also be candidates for
responsive MTL stimulation. Seizure reductions with
responsive MTL stimulation in the RNS System trials were
similar in both subjects who had and had not already under-
gone a MTL resection. However, it should be noted that the
number of subjects with a prior resection was small, reduc-
ing the power of statistical comparisons. Some of the sub-
jects with a prior temporal lobectomy were treated with
responsive MTL stimulation ipsilateral to the resection with
leads placed in residual MTL structures or at the margin of
the resection; some were treated with MTL stimulation con-
tralateral to the resection, and some were treated bilaterally.
These findings suggest that responsive stimulation is an
option if not all of the epileptogenic cortex can be resected.
Furthermore, several case reports suggest that resective sur-
gery and responsive stimulation can sometimes be used syn-
ergistically. Chronic ambulatory ECoG data collected by
the RNS System has been used to identify patients in whom
temporal resections would achieve seizure remission or sub-
stantial palliation. In some of these patients, responsive
MTL stimulation was provided to the contralateral
MTL.26,27
There are limitations to the analyses of the data provided.
First the trials were not powered to provide assessments in
subsets of subjects. Thus, more data will be necessary to
confirm the comparisons of seizure reduction by clinical
demographic characteristic. Second, the identification of
subjects as having MTS was based on physician report and
not a standardized imaging protocol. Furthermore, because
subjects with MTS can have negativeMRI findings and pos-
itive histopathology, some subjects with MTS may not have
been identified. Finally, the data were collected as part of an
open-label study and thus the effect of antiepileptic treat-
ments cannot be clearly defined. However, analysis of sei-
zure reduction in the trials indicated that there was no
difference in seizure response between subjects whose
antiepileptic drugs (AEDs) remained stable and subjects
who had AEDmodification.6,7
Surgical risks related to implantation of the RNS Neu-
rostimulator and leads were well within the expected range
for comparable procedures such as intracranial monitoring
for localization of the seizure focus,6,28–30 epilepsy sur-
gery,5,21,31 and deep brain stimulation for treatment of
movement disorders32 or epilepsy.33,34 The most common
device-related SAEs were implant-site infections, all of
which were superficial soft tissue. The overall risk for an
SAE related to infection per patient implant year was low.
Perioperative hemorrhages occurred in 1.8% of subjects and
were asymptomatic or caused only transient symptoms.
Long-term responsive MTL stimulation was cognitively
and affectively well tolerated in these subjects with medi-
cally intractable MTLE, despite the high prevalence of
moderate depression and suicidality at baseline. Meador
et al.35 reported that 19.4% of the MTLE subjects in the
Pivotal study (n = 95) met criteria for moderate depression
at baseline and 10.8% endorsed suicidality.35 These rates
did not increase with treatment; the rates of depression and
suicidality at 2 years were 16% and 12.6%, respectively.35
Across all 111 subjects (>671 implant years), device-
related or device relation uncertain AEs related to memory
were reported in 6.3%; however, all of these subjects had a
preexisting memory impairment at baseline based on neu-
ropsychological testing. Neuropsychological testing in the
RNS System trials indicated that 56.8% of the Pivotal trial
subjects (n = 95) with MTLE had significant impairment in
memory at baseline.36 Loring et al.36 reported that there
were no cognitive declines with responsive MTL stimula-
tion and that there were improvements in verbal memory,
which, although small in magnitude, were statistically sig-
nificant. A number of studies of open-loop hippocampal
stimulation for temporal lobe epilepsy also found no
adverse effects on memory.10–20 The memory-sparing
effects of MTL stimulation compare favorably to the pro-
gressive memory declines in patients with refractory MTL
who continue to be treated with AEDs.37 This also contrasts
with cognitive outcomes following temporal lobectomy.
Weighted estimates indicate a risk to verbal memory with
left-sided temporal resection of 44%, and 20% for right-
sided surgery.38 Of course, risks to memory are weighed
against the high likelihood of obtaining seizure freedom fol-
lowing temporal lobectomy.
During the Pivotal trial, the MTLE subjects treated with
responsive stimulation reported sustained improvements in
overall quality of life.35 At 2 years of treatment, there were
clinically meaningful improvements in overall quality of
life (QoL) in 41% of subjects, with only 16% reporting
declines. There were also significant improvements in epi-
lepsy targeted and cognitive domains of QoL. The magni-
tude of improvement in QoL was less than that reported
after mesial temporal lobectomy resulting in seizure remis-
sion but greater than that reported with continued medical
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management.2,5,39,40 Because the subjects with MTLE in
the RNS System trials were not considered candidates for
temporal lobectomy, treatment with responsive MTL stimu-
lation resulted in improvements in QoL that would not have
otherwise been possible.
In conclusion, brain-responsive stimulation is a well-tol-
erated and reversible approach to treating MTLE. Medically
refractory patients with MTLE have sustained reductions in
the frequency of clinical seizures that reach 70%. The
response is independent of past epilepsy treatments, and sei-
zure reduction is achieved whether leads are placed within
or close to the hippocampus. There are no stimulation-asso-
ciated sustained AEs on mood or cognition, and some sub-
jects experience memory improvement. Although
responsive stimulation should be considered palliative,
many subjects experience prolonged periods without sei-
zures. Future clinical studies and additional experience with
a variety of stimulation approaches should refine and further
improve the response to treatment. The current clinical
experience indicates that responsive stimulation offers a
much-needed treatment option for patients with medically
intractable MTLE.
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